NuCana (NCNA)

Executive Summary

NuCana plc is a clinical-stage biopharmaceutical company leveraging its proprietary ProTide technology to develop improved versions of established chemotherapies. The company aims to overcome resistance mechanisms and enhance efficacy while reducing toxicity. Despite a promising pipeline, NuCana has faced significant setbacks: multiple Phase 2/3 trials, including NUC-1031 in biliary tract and ovarian cancers, and NUC-3373 in colorectal cancer, were terminated, casting doubt on the platform's clinical viability. Currently, the only actively recruiting trial is the Phase 1/2 study of NUC-7738 combined with pembrolizumab in advanced solid tumors (NCT03829254), with estimated completion in August 2026. With a market capitalization of approximately $8.8 million, the stock reflects deep skepticism. However, positive data from NUC-7738 could validate the ProTide approach and unlock significant value. The company's future hinges on this program, as well as potential strategic partnerships to advance its remaining assets.

Upcoming Catalysts (preview)

• Q4 2026NUC-7738 + Pembrolizumab Phase 1/2 Interim Data20% success
• H2 2026Potential Partnership or Licensing Deal for ProTide Platform15% success